Arrowhead Pharmaceuticals' fair value estimate has recently risen from $47.50 to $55.00 per share, signaling an improved outlook following the FDA approval of Redemplo. This updated price target ...

Ever wondered if Arrowhead Pharmaceuticals’ meteoric rise means the best value is behind it, or if there is still room to capitalize? Let’s break down whether now is actually a good time to buy in.

Arrowhead boasts a diversified RNAi pipeline targeting liver, lung, muscle, CNS, and obesity. Read why I recommend buying and ...

Arrowhead Pharmaceuticals has seen its consensus analyst price target increase from $45 to $47.50 per share, reflecting growing confidence in the company's strategy and market positioning. This ...

Learn more about whether Arrowhead Pharmaceuticals, Inc. or BioMarin Pharmaceutical Inc. is a better investment based on AAII ...

Arrowhead Pharmaceuticals faces key FDA decisions, legal challenges, and trial results. Read the latest analysis on the stock ...